In August 2015, pharmaceutical giant, Shire, made public their new deal with Sanquin, the company that manufactures CINRYZE®. CINRYZE is a drug that is indicated for the rare disease disorder, HAE (Hereditary Angioedema) which, depending on geographic location, threatens the lives of up to 1 in 50,000 people worldwide. And with enhanced access to manufacturing capability, it should enable Shire to increase production and distribution of the drug.
While this news will likely send investors to the bank, let’s not forget who will truly benefit from the deal – patients who live with the daily uncertainty of whether or not they’ll experience a sudden painful swelling attack in any limb or body part that could potentially kill them.
Yes, there’s no doubt this will be a profitable deal, a marriage made in heaven as CINRYZE generated over $500 million dollars alone last year for Shire.
